Frequency and safety of COVID-19 vaccination in children with multisystem inflammatory syndrome: a telephonic interview-based analysis

COVID-19 Vaccine Reactogenicity and Vaccine Attitudes Among Children and Parents/Guardians After Multisystem Inflammatory Syndrome in Children or COVID-19 Hospitalization: September 2021—May 2022

“…22 Interview of 29 children who received COVID-19 vaccine after MIS-C also found the vaccines were well tolerated with no severe reactions. 23 At the time of this investigation Centers for Disease Control and Prevention (CDC) COVID-19 vaccine interim clinical considerations for initiating COVID-19 vaccination in children with a history of MIS-C noted that experts "consider the benefits of COVID-19 vaccination for children and adolescents with a history of MIS-C (ie, a reduced risk of severe disease including potential recurrence of MIS-C after reinfection) to outweigh a theoretical risk of an MIS-like illness or the risk of myocarditis following COVID-19 vaccination" in children who have achieved clinical recovery (including return to normal cardiac function), are at least 90 days from their MIS-C diagnosis, and reside in an area where the COVID-19 community transmission is high. 24 Our objectives were to describe (1) demographic and clinical characteristics of a cohort of children ages <21 years who had MIS-C and subsequently initiated mRNA COVID-19 vaccination;…”

Anti-SARS-CoV-2 Vaccination and PIMS-TS—Friends or Foe? Case Reports and Literature Review

“…The analysis of the presented cases and literature data allows us to conclude that COVID-19 vaccinations in the group of patients with PIMS-TS are almost certainly as safe and effective in preventing PIMS-TS as in the group of healthy children [ 12 , 13 , 14 , 18 , 19 , 20 , 34 , 35 , 36 ]. Our data are consistent with the data provided by the previously mentioned authors.…”

“…For instance, Wisniewski et al reported no adverse effects or PIMS-TS recurrence among 15 vaccinated PIMS-TS patients over 9.5 months [ 18 ]. Similarly, Aykac’s survey of 29 vaccinated post-PIMS-TS patients revealed reactions comparable to those in healthy children, with no significant issues or PIMS-TS relapse [ 19 ]. Hoste et al’s international study of 273 children post-PIMS-TS also showed no concerning post-vaccination symptoms, with a single case of Bell’s paralysis resolving without complications [ 20 ].…”

COVID-19 mRNA BNT162b2 vaccine safety and B-cell and T-cell reactogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS) - preliminary study

“…Similarly to our results, local reactions were most common and no cases of MIS-C/PIMS-TS or myocarditis were reported after vaccination. In Turkey, the retrospective analysis of 29 vaccinated children with a history of PIMS-TS also did not reveal any severe AEs, but at the same time showed that the performance of COVID-19 vaccination after PIMS-TS was suboptimal [68] . Levi Hoste et al conducted an international survey among healthcare professionals to assess experience with the tolerability of the SARS-CoV-2 vaccine in children with a history of PIMS-TS that revealed no safety concerns.…”